Latest Ratios: P/E Ratio -5.7x · EV/EBITDA N/A · ROE -102.0%. (2005–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $78M | $190M | $5M | $5M | $8M | $16M | $36M | $46M | $55M | $9M | $7M |
| Enterprise Value | $74M | $186M | $4M | $299112 | $3M | $11M | $31M | $43M | $50M | $8M | $7M |
| P/E Ratio → | -5.71 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 31.75 | 17.36 | 5.52 | 1.13 | 1.56 | 3.35 | 7.13 | 18.72 | 13.25 | 9.54 | 31.21 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -102.0% | -102.0% | -148.7% | -111.1% | -126.8% | -137.3% | -87.7% | -74.4% | -83.3% | -299.0% | -810.0% |
| ROA | -86.6% | -86.6% | -131.5% | -103.1% | -118.5% | -130.4% | -82.6% | -69.6% | -74.8% | -200.8% | -414.0% |
| ROIC | -121.5% | -121.5% | — | — | — | — | — | — | — | — | -1060.8% |
| ROCE | -83.5% | -83.5% | -148.2% | -111.1% | -126.8% | -137.1% | -87.7% | -75.9% | -83.5% | -299.2% | -810.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.06 | 0.06 | — | — | — | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.41 | -1.26 | -1.05 | -1.04 | -1.01 | -1.01 | -1.07 | -1.04 | -1.31 | -0.93 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -655.20 | -655.20 | — | — | -710.27 | -906.53 | -889.07 | — | -433.30 | -1315.21 | -11665.20 |
Net cash position: cash ($5M) exceeds total debt ($664491)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.88 | 3.88 | 3.26 | 13.73 | 14.05 | 16.81 | 24.15 | 11.23 | 20.55 | 3.67 | 1.98 |
| Quick Ratio | 3.88 | 3.88 | 3.26 | 13.73 | 14.05 | 16.81 | 24.15 | 11.23 | 20.55 | 3.67 | 1.98 |
| Cash Ratio | 3.83 | 3.83 | 3.26 | 13.39 | 13.53 | 15.92 | 23.41 | 10.92 | 20.26 | 3.50 | 0.91 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | 0.0% |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $48M | $2M | $2M | $2M | $1M | $1M | $1M | $979935 | $930290 | $797930 |
Limited cash runway
According to recent financial data, LIXT trades at a price-to-book ratio of 31.75, which suggests that the market is pricing the company based on its intellectual property and clinical pipeline rather than its current tangible asset base or any near-term earnings potential.
The elevated P/B ratio indicates that investors are assigning significant value to the company's PP2A inhibition platform despite the absence of commercial revenue. This valuation appears highly sensitive to clinical trial outcomes, as traditional metrics like P/E are rendered meaningless by the company's persistent net losses.
Based on reported figures, LIXT's ROIC has deteriorated to -22.1% in 2026Q1, reflecting a consistent inability to generate positive returns on invested capital as the firm continues to prioritize R&D spending over the establishment of a self-sustaining, profitable operational model.
The downward trend in ROE and ROIC highlights the structural challenge of funding long-term drug development through equity dilution. Investors should monitor whether future clinical milestones can eventually reverse this decay, though current data suggests that capital is being consumed rather than compounded.
As reported in quarterly statements, LIXT's current ratio declined to 2.78 in 2026Q1 from a peak of 13.73 in 2023Q4, signaling a significant reduction in the company's short-term liquidity cushion as cash reserves are depleted to fund ongoing clinical research and development activities.
While a current ratio of 2.78 may appear adequate in isolation, the rapid contraction suggests that the company's ability to cover its short-term obligations is becoming increasingly constrained. This trend warrants close attention, as the lack of revenue makes the firm entirely dependent on external financing.
The price-to-book ratio is frequently misapplied to LIXT, as it fails to account for the fact that the company's book value is primarily composed of cash and intangible R&D assets rather than productive, revenue-generating capital equipment or inventory.
Investors should instead focus on the burn-to-milestone ratio, which provides a more accurate assessment of the company's operational runway. Relying on P/B may lead to a false sense of security regarding the company's asset backing, ignoring the reality that these assets are rapidly being converted into operating expenses.
Includes 30+ ratios · 21 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LIXT stock.
Lixte Biotechnology Holdings, Inc.'s current P/E ratio is -5.7x. This places it at the 50th percentile of its historical range.
Lixte Biotechnology Holdings, Inc.'s return on equity (ROE) is -102.0%. The historical average is -151.2%.
Based on historical data, Lixte Biotechnology Holdings, Inc. is trading at a P/E of -5.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.